Sunesis Pharmaceuticals Announces Presentations at the EHA Annual Meeting
Université Claude Bernard de Lyon Study Provides Preclinical Validation of Vecabrutinib Activity Against Ibrutinib-Resistant BTK C481S Mutated Lymphomas
ERIC Study Shows Half of Ibrutinib-Relapse CLL Patients Carry BTK C481S Mutations
“Vecabrutinib demonstrated the ability to selectively induce apoptosis in BTK-dependent lymphoma cell lines, and to overcome resistance conferred by the BTK C481S mutation,” said Doctor
“This real-world study confirms that there exists a high frequency of mutations within the Bruton’s tyrosine kinase (BTK) gene at C481, the binding site for ibrutinib, as well as the rarer PLCg2 gene, in CLL patients relapsing under ibrutinib,” said Professor
“We are encouraged by the preclinical data from the laboratory of Professor Salles, which demonstrates vecabrutinib’s activity against ibrutinib-resistant BTK C481S mutated lymphomas,” said
The vecabrutinib study, titled, “Preclinical Validation of Vecabrutinib (SNS-062) Efficiency Against BTK-C481S Mutated Lymphomas” was presented in the Aggressive Non-Hodgkin Lymphoma – nonclinical poster session
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in clinical trials for solid tumors, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking statements, including statements related to Sunesis’ cash sufficiency forecast, the continued development of vecabrutinib (SNS-062), including the timing of Phase 1b/2 trial of vecabrutinib and the therapeutic potential of vecabrutinib, further development and potential of its kinase inhibitor pipeline, and planned development of SNS-510. Words such as “believe,” “expect,” “look forward,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk related to the timing or conduct of Sunesis' clinical trials, including the vecabrutinib Phase 1b/2 trial, the risk that Sunesis' clinical or preclinical studies for vecabrutinib, SNS-510 or other product candidate may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, risks related to the timing or conduct of Sunesis' clinical trials, that Sunesis' development activities for vecabrutinib or SNS-510 could be otherwise halted or significantly delayed for various reasons, that Sunesis may not be able to receive regulatory approval of vecabrutinib, or SNS-510 in the U.S. or
|Investor and Media Inquiries:
Sunesis Pharmaceuticals Inc.
Source: Sunesis Pharmaceuticals, Inc.